Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 13/20 | 0.59 |
| ▸ | BTK | Q06187 | 5/20 | 0.43 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL30140720 | 0.89 | KLKB1 (0.60) | KLKB1BTK | |
| SCHEMBL23469584 | 0.89 | KLKB1 (0.59) | KLKB1BTK | |
| SCHEMBL23469581 | 0.88 | KLKB1 (0.56) | KLKB1BTK | |
| SCHEMBL21712913 | 0.86 | KLKB1 (0.47) | KLKB1BTKL3MBTL1 | |
| SCHEMBL23769633 | 0.86 | KLKB1 (0.46) | KLKB1BTKRBP4L3MBTL1 | |
| SCHEMBL23769622 | 0.84 | KLKB1 (0.45) | KLKB1BTKRBP4L3MBTL1 | |
| SCHEMBL23843093 | 0.84 | KLKB1 (0.45) | KLKB1BTKRBP4L3MBTL1 | |
| SCHEMBL21736642 | 0.83 | KLKB1 (0.44) | KLKB1L3MBTL1 | |
| SCHEMBL20541004 | 0.83 | KLKB1 (0.61) | KLKB1BTK | |
| SCHEMBL30140684 | 0.83 | KLKB1 (0.61) | KLKB1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612523-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-09 | — | — | EP | disclosed |
| EP-3612523-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-09 | — | — | EP | disclosed |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885BTK 1297/4885RBP4 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.